Lecture 11: Sedentary Behaviour, Substance Dependence, and Smoking Dynamics

Course Administration and Academic Milestones

  • Academic Performance Benchmarks:

    • The class average for Midterm 1 was established at 75%75\%.

    • Individual grades are processed and published through teaching assistants.

  • Curricular Adjustments and Schedule:

    • Asynchronous instruction replaces in-person lectures on Wednesday, November 4th, with instructional video content delivered via Canvas.

    • Reading break occurs from November 9th to November 11th, during which no formal university instructional sessions are held.

    • An optional midterm preparation session via Zoom is designated for Thursday, November 12th, featuring an open Question and Answer (Q&A\text{Q\&A}) format that is recorded and distributed via Canvas announcement channels.

    • Midterm 2 is scheduled for Monday, November 16th, evaluating pedagogical content across Chapters 66, 77, and 99, utilizing a combined assessment format of multiple-choice and written-answer questions.

    • Modifications to course scope include the omission of obesity and weight stigma topics from formal lecture time, shifting discussions to office hours.

    • The curricular trajectory designates subsequent modules for dietary nutrition and a post-midterm guest lecturer addressing clinical substance use patterns.

Health Behaviour Change Framework: Implementation and Strategies

  • Assignment 2 Protocol:

    • Soft Deadline 2 is established for Friday, November 6th at 11:59 PM11:59\,\text{PM} on Canvas.

    • The overall activity spans a rigorous 2-week2\text{-week} intervention structure designed to translate health psychology theory into personal lifestyle modification.

    • Week 1 protocol mandates selecting and deploying an initial evidence-based strategy, tracking quantitative and qualitative metrics to observe whether the mechanism facilitates health behaviour change.

    • Week 2 protocol mandates implementing a second distinct strategy (with the option to maintain or retire the primary strategy) while continuing continuous daily tracking and reflective documentation.

  • Core Evidence-Based Intervention Strategies:

    • Positive Reinforcement (Rewards): Establishing contingency reinforcement systems that deliver small, immediate rewards following verifiable incremental progress toward a behavioural goal.

    • Behavioural Modeling: Observational learning acquired by examining the personal experiences of individuals who have successfully attained target behavioural objectives (e.g., structured consultations with successful peers, educational multimedia, or YouTube case studies).

    • Punishment Contingencies: Setting up explicit interpersonal contracts whereby failing to meet weekly behavioural targets incurs a predetermined penalty, such as transferring money, purchasing dinner for an accountability partner, or completing household chores.

    • Managing Negative Reinforcement: Replacing maladaptive coping behaviours that function to terminate negative emotional states (such as using cigarette smoking, alcohol bingeing, or hyper-palatable food consumption to downregulate psychological distress) with alternative stress mitigation techniques.

    • Social Support Enlistment: Recruiting friends, intimate partners, family members, or academic peers to conduct systematic check-ins, provide emotional validation, and enforce behavioural accountability.

    • Self-Efficacy Enhancement: Cultivating task-specific perceived competence through deliberate cognitive reflection on past mastery experiences, resilience under hardship, and individual psychological strengths.

    • Stimulus Control and Cues: Strategic environmental restructuring designed to prompt target health actions, such as scheduling recurring digital device notifications or placing athletic equipment in prominent physical locations (e.g., gym gear positioned adjacent to the exit door).

    • Proactive Problem-Solving: Systematically conducting barrier analyses to anticipate prospective behavioural disruptions and formulating structured coping action plans prior to encountering impediments.

Sedentary Behaviour: Physiological Risks, Patterns, and Moderating Factors

  • Epidemiological Scope and Metabolic Risks:

    • Canadian adults spend approximately 70%70\% of their total waking hours engaging in sedentary behaviours characterized by prolonged bouts of seated or reclining postures.

    • Sustained sedentary duration is an independent risk factor for all-cause premature mortality and a wide spectrum of non-communicable chronic diseases.

    • Metabolic mechanisms involve profound disruptions in endocrine function, specifically acute reductions in cellular insulin sensitivity; this impairs peripheral glucose clearance and produces chronic elevations in postprandial and fasting blood glucose levels.

  • Sedentary Time Fragmentation and Biometric Outcomes:

    • Continuous, unbroken bouts of sedentary time yield significantly worse physiological outcomes than fragmented sedentary time of equivalent aggregate duration.

    • Individuals classified as "Breakers" (those who frequently interrupt seated posture with standing or ambulation) display improved metabolic profiles relative to "Prolongers" (those who sit for long, uninterrupted durations).

    • Interventions that disrupt continuous sitting result in systemic reductions in Body Mass Index (BMI\text{BMI}) and improved glycemic stability.

Waist circumference across quartiles of breaks in sedentary time showing a 6 cm difference between prolongers and breakers
  • Quartile Analysis of Breaks in Sedentary Time:

    • Clinical data tracking waist circumference across quartiles of breaks reveals an inverse relationship:

    • Quartile 1 (Q1\text{Q1}, "Prolongers"): Mean waist circumference reaches approximately 96.8 cm96.8\,\text{cm}.

    • Quartile 2 (Q2\text{Q2}): Mean waist circumference measures approximately 94.3 cm94.3\,\text{cm}.

    • Quartile 3 (Q3\text{Q3}): Mean waist circumference measures approximately 93.7 cm93.7\,\text{cm}.

    • Quartile 4 (Q4\text{Q4}, "Breakers"): Mean waist circumference drops to approximately 90.8 cm90.8\,\text{cm}.

    • This demonstrates an absolute difference of 6 cm6\,\text{cm} in waist circumference between the least frequent breakers (Q1\text{Q1}) and the most frequent breakers (Q4\text{Q4}).

  • Physical Activity Moderation Effects (Ekelund et al., 2016):

    • A harmonized meta-analysis evaluating 1616 prospective cohort studies comprising over 1,000,0001{,}000{,}000 participants examined whether physical activity eliminates the hazardous associations of prolonged sitting.

    • Moderate-to-vigorous physical activity performed at high daily volumes (≥1 hour/day\ge 1\,\text{hour/day}) entirely offsets and eliminates the heightened risk of mortality linked with excessive sitting duration.

    • Qualitative differences exist within sedentary categories: prolonged recreational television viewing is tied to substantially worse cardiovascular and all-cause mortality trajectories compared to occupational sitting, driven in part by concomitant snacking, lower metabolic rates, and prolonged uninterrupted inertia.

Substance Use Continuum: Dependence, Tolerance, and Clinical Disorders

  • Defining the Substance Use Continuum:

    • Physical Dependence: A biological state of neuroadaptation resulting from repeated pharmacological exposure, characterized by:

    • Tolerance: The requirement of progressively larger drug doses to achieve the initial physiological or psychological effect.

    • Withdrawal Syndrome: Specific adverse physiological and psychological reactions emergent when substance concentration declines abruptly after regular administration.

    • Psychological Dependence: A profound cognitive and motivational state marked by a persistent, repeated desire to consume a substance for its reinforcing subjective effects (e.g., emotional regulation, tension relief, analgesia), accompanied by substance-directed cravings and extensive daily time committed to substance acquisition, consumption, or post-use recovery.

    • Substance Use Disorder (SUD\text{SUD}): A diagnostic clinical entity defined by a chronic, problematic cluster of cognitive, behavioural, and physiological symptoms indicating continued substance administration despite consequential functional impairment, occupational deterioration, or severe subjective distress.

  • Diagnostic Orthogonality: Substance Use, Abuse, and Dependence:

    • Use without Abuse: Consuming psychoactive substances under controlled conditions that do not cause significant physical damage, interpersonal crises, or functional impairment (e.g., responsible adult consumption of light-to-moderate alcohol or legal cannabis).

    • Abuse without Dependence: Engaging in hazardous, disruptive, or harmful patterns of drug use without possessing biological neuroadaptation, tolerance, or physiological withdrawal (e.g., periodic, heavy binge-drinking episodes during celebratory social events).

    • Dependence without Abuse: Experiencing neuroadaptive tolerance and physiological withdrawal symptoms within an appropriate, monitored clinical context void of drug-seeking behaviours, non-medical escalation, or lifestyle dysfunctions (e.g., chronic palliative oncology patients managed on long-term therapeutic opioid/morphine protocols for intractable somatic pain).

  • Biopsychosocial Determinants of Drug Dependence:

    • Neurochemical and Genetic Susceptibility: Polymorphic vulnerabilities in mesolimbic and mesocortical circuits, specifically dopaminergic transmission governing reinforcement, hedonics, and salience attribution.

    • Positive Reinforcement Dynamics: Immediate chemical activation of the neurobiological reward system, generating euphoria, perceptual alteration, heightened energy, or a pharmacological "buzz."

    • Negative Reinforcement Dynamics: Removal or alleviation of noxious physical or affective states, such as the suppression of chronic pain, somatic tension, social anxiety, or baseline depressive affect.

    • Personality Constructs: Elevated scores on temperament traits including novelty seeking, sensation seeking, high impulsivity, and elevated baseline risk tolerance.

    • Sociocultural Learning and Expectancies: Vicarious reinforcement acquired through peer modeling, familial substance dynamics, media romanticization, and aggressive commercial marketing campaigns shaping positive outcome expectancies.

Tobacco and Cigarette Smoking: Global and National Epidemiological Trends

  • Global Epidemiology:

    • Tobacco smoking represents the single leading preventable cause of premature death globally.

    • Worldwide epidemiological surveillance reveals that over 1 billion1\,\text{billion} men and 250 million250\,\text{million} women engage in active tobacco smoking, inclusive of both daily and occasional consumers.

Global map of tobacco smoking prevalence among adults
  • Canadian Historical Trajectory (1965–20201965\text{--}2020):

    • Long-term epidemiological tracking across individuals aged 15+15+ indicates a steep, sustained downward secular trend in active smoking rates.

    • In 19651965, overall smoking prevalence exceeded 49%49\%, stratified into approximately 61%61\% among adult males and 38%38\% among adult females.

    • Male consumption experienced a rapid initial decline across the late 1960s1960\text{s} and 1970s1970\text{s}, dropping to approximately 44%44\% by 19791979, while female rates hovered between 37%37\% and 39%39\% during that same period before initiating a synchronized decline.

    • By 20202020, overall population smoking prevalence dropped to roughly 10%10\%, with male smoking stabilizing near 12%12\% and female smoking falling to approximately 9%9\%.

    • The secular decline is not solely attributable to the emergence of electronic nicotine delivery systems (vaping), but reflects decades of compound public health pressure.

Trends in smoking prevalence in Canada from 1965 to 2020 among males, females, and overall population
  • Macro-Level Public Health Interventions:

    • Fiscal Interventions: Imposition of heavy excise taxation on tobacco retail units, elevating consumer prices and leveraging economic price elasticity to depress consumption, particularly among price-sensitive youth.

    • Legislative Clean Indoor Air Acts: Enactment of sweeping bans prohibiting combustible smoking across indoor occupational settings, restaurants, bars, transit hubs, and public facilities.

    • Educational Campaigns: Universal mass-media initiatives warning the public of biological hazards associated with firsthand, secondhand, and environmental tobacco smoke.

    • Point-of-Sale and Packaging Mandates: Implementation of plain packaging legislation alongside mandatory, prominent graphic health warnings and toxic constituent disclosures (such as Health Canada mandates identifying that tobacco smoke contains over 7070 established carcinogens, as well as warning of immediate stroke and pulmonary disease risks).

Evolution of Tobacco Marketing and Counter-Advertising Campaigns

  • Historical Tobacco Marketing Strategies (1920s–1960s1920\text{s}\text{--}1960\text{s}):

    • Weight Management and Appetite Suppression (1920s1920\text{s}): Lucky Strike launched early targeted campaigns directly appealing to women's aesthetic anxieties with the slogan "Reach for a Lucky instead of a sweet" to promote tobacco as an appetite-suppressing alternative to confectionery.

Historical 1950s Camel cigarette advertisement asserting more doctors smoke Camels than any other cigarette
  • Authoritative and Medical Reassurance (1950s–1960s1950\text{s}\text{--}1960\text{s}):

    • Camel developed deceptive ad campaigns declaring "More Doctors smoke Camels than any other cigarette!" referencing a purported national survey of 113,597113{,}597 physicians across specialties to counter mounting consumer anxiety regarding pulmonary carcinogenicity.

    • Ads introduced pseudo-scientific proprietary diagnostics such as the "T-Zone" ("T for taste and T for throat") to persuade consumers that brand selection prevented respiratory irritation.

    • Kent launched the "Micronite Filter" campaign asserting that "More scientists and educators smoke Kent" than any competitor, citing internal surveys claiming 15.3%15.3\% preference among scientists and 20.2%20.2\% among educators to construct an illusion of academic endorsement.

    • Gendered Lifestyle Branding (1950s–1990s1950\text{s}\text{--}1990\text{s}):

  • Masculinized Rebranding: Marlboro was originally launched as a mild female-oriented product before undergoing a complete brand repositioning in the 1950s1950\text{s} and 1970s1970\text{s}, using hyper-masculine iconography (naval commanders, construction workers, and the rugged outdoor cowboy known as the "Marlboro Man") under the banner "Come to where the flavor is."

Vintage Marlboro cigarette advertisement featuring a cowboy lighting a cigarette outdoors
  • Feminist Liberation Co-optation: In 19681968, Philip Morris introduced Virginia Slims, weaponizing emerging feminist empowerment with the tagline "You've come a long way, baby." Later campaigns in the 1990s1990\text{s} featured assertive professional women carrying briefcases paired with corporate slogans declaring "A woman's place is any place her feet will take her."

Vintage Virginia Slims advertisement associating cigarette smoking with women's liberation
  • Evolution of Public Health Counter-Marketing:

    • Subversive Parody Advertising (19981998): The California Department of Health Services, financed by the voter-approved Tobacco Tax Initiative, launched aggressive counter-campaigns directly parodying tobacco marketing. These featured iconic Western cowboys on horseback set against dramatic sunsets with subversive dialogue: "I miss my lung, Bob" and "Bob, I've got emphysema."

Anti-smoking parody billboard created by California Department of Health Services stating 'I miss my lung, Bob'
  • Emotive Narrative Campaigns (Current Day): Modern campaigns by the Centers for Disease Control and Prevention (CDC\text{CDC}) known as "Tips from Former Smokers" utilize visceral, relatable personal narratives over clinical statistics. These showcase real former smokers living with permanent surgical disfigurements, cervical stomas, open tracheostomies, and post-thoracotomy scarring.

CDC Tips From Former Smokers campaign portraits depicting health consequences of smoking

Etiology of Smoking Initiation in Adolescents

  • Primary Psychosocial Risk Factors:

    • Parental Smoking Modeling: Growing up in a household with at least one nicotine-dependent parent increases initiation likelihood through observational social learning and elevated home tobacco access.

    • Peer Social Influence: Experiencing acute subjective and structural peer pressure to smoke as an index of social conformity or status display within peer cliques.

    • Family Stress Exposure: Experiencing severe, unaddressed family disruption, emotional conflict, or socio-environmental instability, which increases reliance on external chemical coping agents.

    • Socioeconomic Vulnerability: Living in lower socioeconomic status (SES\text{SES}) households and neighborhoods characterized by elevated targeted marketing, reduced recreational alternatives, and heightened chronic ambient distress.

    • Cognitive Optimism Bias: Endorsing inaccurate risk perceptions that experimental tobacco use is benign, accompanied by an erroneous subjective belief that physiological harm is exclusively restricted to late-life adulthood.

Biological and Neurochemical Mechanisms of Nicotine

  • Pharmacokinetics and Central Nervous System Stimulation:

    • Nicotine rapidly crosses the blood-brain barrier within seconds of inhalation, binding to nicotinic acetylcholine receptors (nAChRs\text{nAChRs}) distributed across the central and autonomic nervous systems.

    • Triggers immediate downstream release of dopamine within the nucleus accumbens, reinforcing dependence, alongside systemic epinephrine (adrenaline) surges.

    • Induces acute cerebral arousal, heightening vigilance, sustained attention, and transient states of increased cognitive alertness.

    • Produces transient analgesia and sensory suppression, increasing behavioral reliance on cigarettes during periods of subjective distress.

Anatomical diagram detailing the physiological and neurochemical effects of nicotine on the human body
  • Systemic Physiological Cascade:

    • Cardiovascular Activation: Sympathetic nervous system excitation elevates resting heart rate, increases systemic arterial blood pressure, and places extra hemodynamic demands on cardiac muscle.

    • Peripheral Vasoconstriction: Marked reduction in vascular diameter reduces blood flow and oxygen delivery to the distal extremities (e.g., fingers and toes).

    • Skeletal Muscle and Emotional Regulation: At elevated circulating plasma titers, paradoxically stimulates neuromuscular pathways that induce systemic skeletal muscle relaxation and triggers neurochemical cascades that attenuate psychological stress.

    • Metabolic and Dietary Alterations: Central appetite suppression that selectively attenuates dietary cravings for simple carbohydrates.

Tobacco-Attributable Global Morbidity and Mortality

  • Global Disease Burden Profile:

    • Chronic tobacco use functions as an established, direct etiologic risk factor in 66 of the 88 leading global causes of mortality identified by the World Health Organization (WHO\text{WHO}, based on 20052005 longitudinal surveillance data).

    • Estimated annual global fatalities directly precipitated by tobacco consumption reached 5,395,0005{,}395{,}000 individuals across monitored diagnostic categories.

Bar graph showing tobacco use as a major risk factor for six of the eight leading causes of death worldwide in 2005
  • Pathology-Specific Mortality Breakdown (WHO 2005\text{WHO}\ 2005 Data):

    • Ischaemic Heart Disease: Total deaths reached 6,704,0006{,}704{,}000, with tobacco identified as the primary etiological risk factor in 885,000885{,}000 of those deaths.

    • Cerebrovascular Disease (Stroke): Total deaths reached 5,280,0005{,}280{,}000, with tobacco responsible for 466,000466{,}000 of those deaths.

    • Lower Respiratory Infections: Total deaths reached 3,532,0003{,}532{,}000, with tobacco contributing to 154,000154{,}000 of those deaths.

    • Chronic Obstructive Pulmonary Disease (COPD\text{COPD}): Total deaths reached 1,761,0001{,}761{,}000, with tobacco responsible for 1,253,0001{,}253{,}000 of those deaths (>71%> 71\%).

    • HIV/AIDS: Total deaths reached 2,138,0002{,}138{,}000 (unrelated to tobacco exposure).

    • Diarrhoeal Diseases: Total deaths reached 1,682,0001{,}682{,}000 (unrelated to tobacco exposure).

    • Tuberculosis: Total deaths reached 1,270,0001{,}270{,}000, with tobacco contributing to 141,000141{,}000 of those deaths.

    • Trachea, Bronchus, and Lung Cancers: Total deaths reached 1,290,0001{,}290{,}000, with non-tobacco causes accounting for only 338,000338{,}000 deaths while direct tobacco use caused 952,000952{,}000 deaths (>73.7%> 73.7\%).

    • Other Tobacco-Caused Diseases: Additional tobacco-induced pathophysiological states accounted for an auxiliary 1,544,0001{,}544{,}000 global deaths.

Smoking Cessation Methodologies: Pharmacotherapy and Behavioural Interventions

  • Cessation Pathways and Comparative Modalities:

    • The empirical majority of long-term ex-smokers achieve permanent abstinence unassisted via self-directed cessation ("cold turkey").

    • Professional cessation trajectories include brief clinical counseling delivered by primary care providers, structured evidence-based pharmacotherapies, and intensive cognitive-behavioural psychotherapies.

    • Clinical synergy is established: combining pharmacological agents with structured psychological therapy yields superior long-term abstinence rates compared to either intervention deployed in isolation.

Transdermal nicotine patch applied to an upper arm as nicotine replacement therapy
  • Pharmacological Agents for Smoking Cessation:

    • Nicotine Replacement Therapy (NRT\text{NRT}): Comprises transdermal delivery patches, sublingual chewing gums, lozenges, and inhalators. Delivers controlled, low-dose medicinal nicotine into the circulation to attenuate craving intensity and alleviate somatic withdrawal without exposing lungs to toxic combustion carcinogens.

    • Zyban (Bupropion Hydrochloride): A monocyclic atypical antidepressant functioning as a dual norepinephrine-dopamine reuptake inhibitor and non-competitive nicotinic receptor antagonist, reducing withdrawal severity and craving spikes.

    • Champix/Chantix (Varenicline Tartrate): A synthetic high-affinity selective nicotinic acetylcholine receptor partial agonist targeting the α4β2\alpha_4\beta_2 receptor subtype. Partially activates receptors to ease craving and withdrawal while simultaneously blocking exogenous nicotine binding to blunt reward sensations from smoking lapses.

    • Cravv (Cytisine): A plant-derived bioactive alkaloid functioning as a natural health product that partially blocks nicotinic receptors, offering an affordable pharmacological option for cessation.

  • Cochrane Meta-Analytic Pharmacotherapy Comparison (20132013):

    • Systematic review and network meta-analysis evaluated the comparative therapeutic efficacy of NRT\text{NRT}, Bupropion (Zyban), and Varenicline (Champix).

    • All three active pharmacological classes proved significantly superior to placebo conditions in producing verified long-term smoking cessation.

    • Varenicline (Champix) was identified as the most efficacious single agent, increasing the odds of sustained cessation by nearly threefold (≈3×\approx 3\times) relative to placebo, outperforming both bupropion and single-agent NRT\text{NRT}.

  • Behavioural and Cognitive-Behavioural Therapy (CBT\text{CBT}) Protocols:

    • Designating a Formal Quit Date: Selecting an unambiguous, non-negotiable target date for complete smoking cessation to crystallize psychological commitment and establish a structured behavioural timeline.

    • Social Accountability Partnerships: Recruiting an active peer, spouse, or mentor ("quit buddy") to establish continuous mutual accountability and provide interpersonal reassurance during craving surges.

    • Contingency Management and Positive Reinforcement: Implementing structured positive reinforcement schedules that supply tangible rewards for verifiable periods of verified tobacco abstinence.

    • Stimulus Control and Cue Avoidance: Mapping out individualized environmental antecedents that trigger drug cravings (e.g., social gatherings, post-meal timing, driving, alcohol consumption) and systematically eliminating or avoiding those stimuli.

    • Motivational Interviewing (MI\text{MI} / Motivational Enhancement Therapy): A collaborative, person-centered clinical counseling methodology designed to explore and resolve ambivalence regarding cessation, enhancing internal motivation and personal commitment to change.

    • Standardized Cessation Infrastructure: Utilization of public health smoking cessation resources, such as the British Columbia Lung Foundation's QuitNow platform (www.quitnow.ca), providing evidence-based behavioural plans, peer-led networks, and professional telephone coaching.